These antibodies can be used in various applications including Western blot, immunoprecipitation, flow cytometry, immunohistology of frozen sections and inhibition studies
Cambridge BioScience now offers monoclonal antibodies against the extracellular domain of toll-like receptor 2.
Direct and specific interaction with TLR2 has been demonstrated using surface plasmon resonance analysis.
These antibodies, produced by HyCult Biotechnology (HBT), can be used in various applications including Western blot, immunoprecipitation, flow cytometry, immunohistology of frozen sections and inhibition studies.
Experiments have shown antagonistic anti-TLR2 monoclonal antibody prevents TLR2-driven shock-like syndromes.
TLR2 has been identified as a receptor that is central to the innate immune response to lipoproteins of Gram-negative bacteria, several whole Gram-positive bacteria, as well as a receptor for peptidoglycan and lipoteichic acid and other bacterial cell membrane products.
Infections with Gram-negative or Gram positive bacteria provide TLR2-specific agonists and are a major cause of severe sepsis.
These products are available from Cambridge BioScience in the UK and Ireland only.
